A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Part of paid clinical trials in West Valley City, Utah.

Sponsor
Verastem, Inc.
Study ID
NCT07644559
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • G12D Mutated KRAS
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VS-7375 — DRUG
    Taken by mouth
  • cetuximab — DRUG
    Subcutaneous infusion

Study Details

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: VS-7375 Monotherapy
  • Experimental: VS-7375 + cetuximab 2L PDAC
  • Experimental: VS-7375 + cetuximab 1L PDAC

Primary Outcome Measure

Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
START- Mountain RegionWest Valley CityUtah84119
Julianna Daley
[email protected]
William McKean, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in West Valley City, UT

By research site
START- Mountain Region· West Valley City, UT

Related Studies